Skip to main content
. Author manuscript; available in PMC: 2019 Aug 6.
Published in final edited form as: Eur Urol. 2017 Sep 28;73(1):62–68. doi: 10.1016/j.eururo.2017.09.008

Table 2 –

Most common (≥1% of patients in any group) sites of distant recurrence

Site of relapse Patients, n (%)
Sunitinib (n = 309) Placebo (n = 306)
Lung 40 (13) 49 (16)
Lymph node 21 (6.8) 26 (8.5)
Retroperitoneum 16 (5.2) 20 (6.5)
Liver 11 (3.6) 14 (4.6)
Adrenal gland 10 (3.2) 6 (2)
Bone 3 (1) 7 (2.3)
Pancreas 4 (1.3) 5 (1.6)
Brain 3 (1) 4 (1.3)
Peritoneum/omentum 3 (1) 4 (1.3)
Mediastinum 1 (0.3) 4 (1.3)